CentroDerm GmbH
- Address
- lock Available on a paid plan
Immune System Diseases (C20)
At CentroDerm GmbH the dermatology department conducts research on immune system diseases, with a focus on seasonal allergies. One trial evaluates a subcutaneous allergoid for birch pollen‑induced allergic rhinitis and rhinoconjunctivitis, measuring symptom reduction and medication need during the peak pollen season.
- Allergen immunotherapy efficacy
- Subcutaneous administration strategies
- Seasonal symptom tracking
- Placebo‑controlled study design
- Patient‑reported outcome measures
Based in Wuppertal, Germany, the site manages 7 active trials with 3 investigators, emphasizing patient‑centered approaches to allergy management.
Skin and Connective Tissue Diseases (C17)
The dermatology unit at CentroDerm GmbH advances treatments for a range of skin conditions, including moderate‑to‑severe plaque psoriasis, papulopustular acne, actinic keratosis, and moderate to severe platysma prominence. Ongoing studies assess long‑term safety of novel biologics, compare topical gel formulations, and test a potassium hydroxide solution for precancerous lesions.
- Biologic therapy safety profiling
- Comparative efficacy of topical gels
- Non‑invasive imaging of lesion response
- Chemical field treatment for actinic keratosis
- Minimally invasive procedures for facial prominence
With a portfolio of 7 trials, the clinic demonstrates a robust commitment to improving outcomes for patients with chronic skin diseases.
Broad Dermatology Research
CentroDerm GmbH operates as a non‑commercial hospital‑clinic in Wuppertal, delivering a diverse portfolio of dermatology trials that span immune‑mediated and structural skin disorders. The research program integrates innovative therapies, safety monitoring, and patient‑focused endpoints to enhance diagnostic and treatment standards.
- Multi‑center collaboration across Europe
- Integration of novel diagnostic imaging
- Evaluation of both systemic and topical agents
- Long‑term safety and efficacy assessments
- Alignment with regulatory and ethical guidelines
The site’s 7 clinical investigations, led by 3 investigators, reflect a strong emphasis on advancing dermatologic care without commercial sponsorship.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Dermapharm AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Inmunotek S.L.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CentroDerm GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | Amgen Inc. | Phase III | Not Recruiting | Oct 2023 | Jun 2026 |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azelastine Hydrochloride | 2 | Unknown | 2024-10-28 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.